Image

Global Hereditary Cancer Testing Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Jun 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Hereditary Cancer Testing Market, By Diagnosis Type (Biopsy and Imaging), Technology (Sequencing, PCR, and Microarray), and End User (Hospital, Clinics, and Diagnostic Centers)– Industry Trends and Forecast to 2029

Hereditary Cancer Testing Market

Market Analysis and Size

Genetic testing for hereditary cancer syndromes utilising next-generation sequencing technology is gradually moving from research to clinical settings. Multi-gene panels are being used in clinical settings to help people make better decisions about primary and secondary prevention efforts and genetically informed therapy alternatives. Because certain cancer syndromes, such as Lynch, Li-Fraumeni, and hereditary breast and ovarian cancer syndromes, are hereditary, test results have consequences for both the initial tested individual and their genetic family members. When correct genetic risk information is communicated, prospective affected family members can be tested and, if necessary, benefit from increased prevention methods.

Data Bridge Market Research analyses that the hereditary cancer testing  market which was USD 1.90 billion in 2021, would rocket up to USD 3.83 billion by 2029, and is expected to undergo a CAGR of 9.15% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

A hereditary cancer is any cancer formed by a hereditary gene mutation. Injurious alternatives in some genes are known to be linked with an enlarged risk of developing cancer. Genetic testing helps in assessing an individual’s chance of developing cancer in his or her lifetime. This can be done by searching for alterations in one’s genes, chromosomes, or proteins. Genetic tests are available for a rare types of cancer. These cover breast cancer, ovarian cancer, thyroid cancer, prostate cancer, pancreatic cancer, colon cancer, sarcoma and kidney cancer.            

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Diagnosis Type (Biopsy and Imaging), Technology (Sequencing, PCR, and Microarray), and End User (Hospital, Clinics, and Diagnostic Centers)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

CENTOGENE N.V. (Germany), Ambry Genetics (U.S), Myriad Genetics, Inc.  (U.S), NeoGenomics Laboratories (U.S), Quest Diagnostics (U.S ), PreventionGenetics (U.S), Fulgent Genetics (U.S), Invitae Corporation (U.S), Medical Diagnostic Laboratories, LLC. (U.S), Color (U.S), Asper Biogene (Europe), Natera Inc. (U.S), Caris Life Sciences(U.S), Shimadzu Corporation (U.S), Progenity_Inc. (U.S), ARUP Laboratories(U.S)

Market Opportunities

  • Growing pervasiveness of hereditary cancer due to alteration
  • Efficacy and cost-effectiveness over out-of-date challenging procedures

Hereditary Cancer Testing Market Dynamics

Drivers

  • Increasing Prevalence of Hereditary Cancer

Cancer is a genetic disorder produced due to definite changes in genes that administrate cell efficacy, mainly moving their growth and duplication. Hereditary genetic mutations are the reason of ~5–10% of all cancers. The detectives have related mutations in precise genes with added 50 hereditary cancer syndromes which effects entities in emerging certain cancers.

  • Development in genomic technology

Breast cancer is one of the most collective cancers in the world affecting almost 12.5% of women during their lifetime and 5%–10% of these patients have a hereditary form. BRCA1 and BRCA2 genes are the two most mutual mutated genes, but additional genes connected with hereditary breast cancer are emerging. New developments in genomic skills have directed to parallel testing of multiple genes. Modified next generation sequencing panels are now provides the immediate analysis of breast cancer predilection genes, from high to the in-between penetrant genes.

Opportunities

  • Increasing prevalence of hereditary cancer

Due to mutation in the genes is one of the factor which impacts the early detection of hereditary cancer which will increase the growth of market while efficacy and cost-effectiveness over traditional testing methods is also a factor driving the market growth. Moreover, mounting demand for initial discovery and precise analysis is a feature that drives market growth.

Restraints/Challenges

The performance of hereditary multigene panel testing rises several issues, such as the measures that the patients have to meet in order to undertake the test and the patient’s clinical association. The operation of the test must be in agreement with the positions for genetic testing familiar in the (American Society of Clinical Oncology, Inc.) ASCO policy. This can limit the number of tests. Nevertheless, difficulties in recovering the complete genomic data for early detection and prevention act as a restraining factor for the market. Furthermore, there is still some unemployed market which will produce gainful occasions with development information for the market.

This hereditary cancer testing  market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hereditary cancer testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Hereditary Cancer Testing Market

Many of the industries across the world have been harmfully wedged over the last 18 months. This can be attributed to significant disturbances experienced by their respective industrialized and supply-chain processes as a result of various precautionary lockdowns, as well as other restrictions that governing establishments across the globe enforced. The same smears to the global hereditary cancer testing market. Furthermore, consumer demand has also subsequently reduced as persons are now stronger on eradicating non-essential expenses from their respective budgets as the general economic status of most persons have been severely affected by this outbreak. These aforementioned elements are predictable to burden the revenue trajectory of the global hereditary cancer testing market over the forecast timeline.

Recent Development

  • In June 2020, Invitae and ArcherDX announced Monday morning that the two genetic testing companies have agreed to syndicate in command to expand their footmark in the cancer genetics and precision oncology space.

Global Hereditary Cancer Testing Market Scope

The hereditary cancer testing market is segmented on the basis of type, indication and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

 Type

  • Multi Panel Test
  • Single-site Genetic Test

Indication

  • Breast Cancer
  • Ovarian Cancer
  • Colorectal Cancer
  • Others

End-user

  • Diagnostic Laboratory
  • Hospitals
  • Others

Hereditary Cancer Testing Market Regional Analysis/Insights

The hereditary cancer testing market is analysed and market size insights and trends are provided by country, type, indication and end-user as referenced above.

The countries covered in the hereditary cancer testing  market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

In North America, the market is anticipated to take a giant leap in revenue generation due to rising throwaway revenue, availability of advanced healthcare infrastructure, and increasing adoption of genetic testing in the region. Increasing profitable approval to deportment hereditary testing is among major factors stimulating the regional market's growth.

 Asia-Pacific and Europe are expected to a significant growth rate in the coming years due to growing cancer cases and developing healthcare sectors.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The hereditary cancer testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for hereditary cancer testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the hereditary cancer testing market. The data is available for historic period 2010-2020.

Competitive Landscape and Hereditary Cancer Testing Market Share Analysis

The hereditary cancer testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hereditary cancer testing market.

Some of the major players operating in the hereditary cancer testing market are:

  • CENTOGENE N.V. (Germany)
  • Ambry Genetics (U.S)
  • Myriad Genetics, Inc.  (U.S)
  • NeoGenomics Laboratories (U.S)
  • Quest Diagnostics (U.S)
  • PreventionGenetics (U.S)
  • Fulgent Genetics (U.S)
  • Invitae Corporation (U.S)
  • Medical Diagnostic Laboratories, LLC. (U.S)
  • Color (U.S)
  • Asper Biogene (Europe)
  • Natera Inc. (U.S)
  • Caris Life Sciences (U.S)
  • Shimadzu Corporation (U.S)
  • Progenity Inc. (U.S)
  • ARUP Laboratories (U.S)

Research Methodology: Global Hereditary Cancer Testing Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The Hereditary Cancer Testing Market value is expected USD 3.83 billion by 2029.
The Hereditary Cancer Testing Market is to grow at a CAGR of 9.15% during the forecast by 2029.
On the basis of technology, the Hereditary Cancer Testing Market is segmented into Sequencing, PCR, and Microarray.
The major players operating in the Hereditary Cancer Testing Market are CENTOGENE N.V. (Germany), Ambry Genetics (U.S), Myriad Genetics, Inc. (U.S), NeoGenomics Laboratories (U.S), Quest Diagnostics (U.S ), PreventionGenetics (U.S), Fulgent Genetics (U.S), Invitae Corporation (U.S), Medical Diagnostic Laboratories, LLC. (U.S), Color (U.S), Asper Biogene (Europe), Natera Inc. (U.S), Caris Life Sciences(U.S), Shimadzu Corporation (U.S), Progenity_Inc. (U.S), ARUP Laboratories(U.S).